QUALITY BY DESIGN AND CHARACTERIZATION OF EDARAVONE SLN TO IMPROVE BRAIN DELIVERY BY NASAL ROUTE FOR THE TREATMENT OF ALZHEIMER’S DISEASE

CH. BHAVANI; P. BALAJI

doi:10.22159/ijap.2026v18i1.55684

Authors

CH. BHAVANI Department of Pharmaceutics, School of Pharmaceutical sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS). Pallavaram, Chennai-600117, Tamilnadu, India. Department of Pharmaceutics, CMR College of Pharmacy, Medchal, Hyderabad, Telangana-501401, India https://orcid.org/0000-0002-1539-583X
P. BALAJI Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, Tamilnadu, India https://orcid.org/0000-0001-5317-1661

DOI:

https://doi.org/10.22159/ijap.2026v18i1.55684

Keywords:

Solid lipid nanoparticles, Central composite design, Alzheimer’s disease, Design of experiments, Entrapment efficiency, Edaravone

Abstract

Objective: The present study aims at formulation development of solid lipid nanoparticles of Edaravone(EDN), for nasal administration to improve the permeation through blood brain barrier for therapeutically effect on Alzheimer’s disease.

Methods: Solid lipid nanoparticles(SLN) are formulated by using the lipid core of Glyceryl monostearate and Tween80 as surfactant through emulsification, solvent evaporation technique and optimized by using 3²central composite design(CCD) secondary overlay plots. Selection of the optimized formulation based on the dependable factors like entrapment efficiency(EE), particle size, polydispersity index(PDI), zeta potential and drug release studies. The selected optimized formulation was subjected to test the behavioral changes in Wister rats.

Results: the final optimized formulation was observed as particle size of <200nm. Entrapment efficiency of 87%, zeta potential of -21.23mEV and drug release of 84%. In vivo studies with the SLN encapsulated EDN showed better memory retention when comparing with the pure drug formulation. Y-Maze test behavioral score with control group 24.5±3.39% was considerably lower with the ENP-treated group (53.5±4.41% for high dose).

Conclusion: EDN encapsulated SLN delivered through the nasal route of administration has the better therapeutical applications in nano formulation strategies.

References

[1] D. Astruc, “Introduction to nanomedicine,” Jan. 01, 2016, MDPI AG. doi: 10.3390/molecules21010004.

[2] N. Pentu et al., “Targeted Lipid Based Vesicles as Drug Delivery Systems in Cancer Treatment,” Int J Pharm Investig, vol. 15, no. 3, pp. 770–776, Apr. 2025, doi: 10.5530/ijpi.20250171.

[3] V. Girdhar, S. Patil, S. Banerjee, and G. Singhvi, “Nanocarriers For Drug Delivery: Mini Review,” Current Nanomedicine, vol. 8, no. 2, pp. 88–99, Nov. 2018, doi: 10.2174/2468187308666180501092519.

[4] A. Mistry, S. Stolnik, and L. Illum, “Nanoparticles for direct nose-to-brain delivery of drugs,” Int J Pharm, vol. 379, no. 1, pp. 146–157, Sep. 2009, doi: 10.1016/j.ijpharm.2009.06.019.

[5] D. Mittal, A. Ali, S. Md, S. Baboota, J. K. Sahni, and J. Ali, “Insights into direct nose to brain delivery: current status and future perspective,” Drug Deliv, vol. 21, no. 2, pp. 75–86, Mar. 2014, doi: 10.3109/10717544.2013.838713.

[6] S. Pandey et al., “Nose-to-brain delivery of microcarrier in the treatment of neurodegenerative diseases,” J Appl Pharm Sci, vol. 15, no. 3, pp. 22–29, 2025, doi: 10.7324/JAPS.2025.211124.

[7] F. H. Pottoo et al., “Lipid-based nanoformulations in the treatment of neurological disorders,” Jan. 02, 2020, Taylor and Francis Ltd. doi: 10.1080/03602532.2020.1726942.

[8] P. Giunchedi, E. Gavini, and M. C. Bonferoni, “Nose-to-brain delivery,” Feb. 01, 2020, MDPI AG. doi: 10.3390/pharmaceutics12020138.

[9] M. E. N. P. Ribeiro et al., “Solubilisation capacity of Brij surfactants,” Int J Pharm, vol. 436, no. 1–2, pp. 631–635, Oct. 2012, doi: 10.1016/j.ijpharm.2012.07.032.

[10] H. Shimizu et al., “Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects,” Clin Pharmacol Drug Dev, vol. 10, no. 10, pp. 1188–1197, Oct. 2021, doi: 10.1002/cpdd.952.

[11] H. Shimizu et al., “Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis,” Clin Ther, vol. 45, no. 12, pp. 1251–1258, Dec. 2023, doi: 10.1016/j.clinthera.2023.09.025.

[12] A. Dinda, I. Biswal, P. Chowdhury, and R. Mohapatra, “Formulation Development and Evaluation of Paclitaxel Loaded Solid Lipid Nanoparticles Using Glyceryl Monostearate,” J Appl Pharm Sci, vol. 3, no. 08, pp. 133–138, 2013, doi: 10.7324JAPS.2013.3823.

[13] T. Helgason, T. S. Awad, K. Kristbergsson, D. J. McClements, and J. Weiss, “Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN),” J Colloid Interface Sci, vol. 334, no. 1, pp. 75–81, Jun. 2009, doi: 10.1016/j.jcis.2009.03.012.

[14] R. H. M. Èller, K. M. Èder, and S. Gohla, “Solid lipid nanoparticles (SLN) for controlled drug delivery ± a review of the state of the art.” [Online]. Available: www.elsevier.com/locate/ejphabio

[15] H. Hassan, S. K. Adam, E. Alias, M. M. R. M. M. Affandi, A. F. Shamsuddin, and R. Basir, “Central composite design for formulation and optimization of solid lipid nanoparticles to enhance oral bioavailability of acyclovir,” Molecules, vol. 26, no. 18, Sep. 2021, doi: 10.3390/molecules26185432.

[16] J. Hao et al., “Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design,” European Journal of Pharmaceutical Sciences, vol. 47, no. 2, pp. 497–505, Sep. 2012, doi: 10.1016/j.ejps.2012.07.006.

[17] M. Tavares Luiz et al., “Design of experiments (DoE) to develop and to optimize nanoparticles as drug delivery systems,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 165, pp. 127–148, Aug. 2021, doi: 10.1016/j.ejpb.2021.05.011.

[18] B. V. Laxmi, D. V. R. N. Bhikshapathi, V. V Rajesham, P. Poornima, P. Sandhya, and G. Arjun, “MAXIMIZING THE POTENTIAL OF IBRUTINIB: MULTI-FACTOR OPTIMIZATION AND INTERACTION ANALYSIS FOR IMPROVED NANOBUBBLE FORMULATION AND BIOAVAILABILITY PERFORMANCE,” 2025, doi: 10.22159/ijap.2025v17i5.54081.

[19] V. C. E, A. Azhakesan, and N. Pentu, “QBD APPROACH FOR THE DEVELOPMENT OF NANOSPONGE LOADED TOPICAL GEL OF FUCOIDAN FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: IN VITRO, EX-VIVO, AND IN VIVO ASSESSMENT,” 2025, doi: 10.22159/ijap.2025v17i2.52746.

[20] E. B. Souto et al., “Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery,” Feb. 01, 2022, Elsevier Ltd. doi: 10.1016/j.heliyon.2022.e08938.

[21] S. Sathya, B. G. Manogari, K. Thamaraiselvi, S. Vaidevi, K. Ruckmani, and K. P. Devi, “Phytol loaded PLGA nanoparticles ameliorate scopolamine-induced cognitive dysfunction by attenuating cholinesterase activity, oxidative stress and apoptosis in Wistar rat,” Nutr Neurosci, vol. 25, no. 3, pp. 485–501, Mar. 2022, doi: 10.1080/1028415X.2020.1764290.

[22] M. K. Shehata, A. A. Ismail, and M. A. Kamel, “Nose to Brain Delivery of Astaxanthin–Loaded Nanostructured Lipid Carriers in Rat Model of Alzheimer’s Disease: Preparation, in vitro and in vivo Evaluation,” Int J Nanomedicine, vol. Volume 18, pp. 1631–1658, Mar. 2023, doi: 10.2147/IJN.S402447.

[23] M. Subramanian, K. Munuswamy, and P. Pitchaimuthu, “Neuroprotective Effects of Withaferin-A Nanoparticles on Scopolamine Rat Model of Alzheimer’s Disease,” Indian Journal of Pharmaceutical Education and Research, vol. 57, no. 3, pp. 620–625, Jul. 2023, doi: 10.5530/ijper.57.3s.70.

[24] S. M. Danish et al., “Intranasal Cerium Oxide Nanoparticles Ameliorate Cognitive Function in Rats with Alzheimer’s via Anti-Oxidative Pathway,” Pharmaceutics, vol. 14, no. 4, p. 756, Mar. 2022, doi: 10.3390/pharmaceutics14040756.

[25] T. Maurice, B. P. Lockhart, and A. Privat, “Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction,” Brain Res, vol. 706, no. 2, pp. 181–193, Jan. 1996, doi: 10.1016/0006-8993(95)01032-7.

[26] R. Morris, “Developments of a water-maze procedure for studying spatial learning in the rat,” J Neurosci Methods, vol. 11, no. 1, pp. 47–60, May 1984, doi: 10.1016/0165-0270(84)90007-4.

[27] C. Demetzos, “Differential Scanning Calorimetry (DSC): A tool to study the thermal behavior of lipid bilayers and liposomal stability,” J Liposome Res, vol. 18, no. 3, pp. 159–173, Sep. 2008, doi: 10.1080/08982100802310261.

[28] A. C. Correia, J. N. Moreira, J. M. Sousa Lobo, and A. C. Silva, “Design of experiment (DoE) as a quality by design (QbD) tool to optimise formulations of lipid nanoparticles for nose-to-brain drug delivery,” Expert Opin Drug Deliv, vol. 20, no. 12, pp. 1731–1748, Dec. 2023, doi: 10.1080/17425247.2023.2274902.

[29] L. X. Yu et al., “Understanding pharmaceutical quality by design,” 2014, Springer New York LLC. doi: 10.1208/s12248-014-9598-3.

[30] S. Gupta, R. Kesarla, N. Chotai, A. Misra, and A. Omri, “Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability,” Biomed Res Int, vol. 2017, Jan. 2017, doi: 10.1155/2017/5984014.

[31] B. Shah, D. Khunt, H. Bhatt, M. Misra, and H. Padh, “Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters,” European Journal of Pharmaceutical Sciences, vol. 78, pp. 54–66, Oct. 2015, doi: 10.1016/j.ejps.2015.07.002.

[32] A. Pezeshki and M. B. Zirak, “Effect of Surfactant Concentration on the Particle Size, Stability and Potential Zeta of Beta carotene Nano Lipid Carrier,” 2015. [Online]. Available: https://www.researchgate.net/publication/319458168

[33] G. F. Reed, F. Lynn, and B. D. Meade, “Use of coefficient of variation in assessing variability of quantitative assays,” Clin Diagn Lab Immunol, vol. 9, no. 6, pp. 1235–1239, Nov. 2002, doi: 10.1128/CDLI.9.6.1235-1239.2002.

[34] M. Yasir et al., “Solid lipid nanoparticles for nose to brain delivery of donepezil: formulation, optimization by Box–Behnken design, in vitro and in vivo evaluation,” Artif Cells Nanomed Biotechnol, vol. 46, no. 8, pp. 1838–1851, Nov. 2018, doi: 10.1080/21691401.2017.1394872.

[35] S. Kwak, “Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant!,” J Lipid Atheroscler, vol. 12, no. 2, pp. 89–95, May 2023, doi: 10.12997/jla.2023.12.2.89.

[36] M. A. Vakilinezhad, S. Tanha, H. Montaseri, R. Dinarvand, A. Azadi, and H. A. Javar, “Application of response surface method for preparation, optimization, and characterization of nicotinamide loaded solid lipid nanoparticles,” Adv Pharm Bull, vol. 8, no. 2, pp. 245–256, 2018, doi: 10.15171/apb.2018.029.

[37] A. Siddiqui, A. Alayoubi, Y. El-Malah, and S. Nazzal, “Modeling the effect of sonication parameters on size and dispersion temperature of solid lipid nanoparticles (SLNs) by response surface methodology (RSM),” Pharm Dev Technol, vol. 19, no. 3, pp. 342–346, May 2014, doi: 10.3109/10837450.2013.784336.

[38] J. Hao et al., “Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design.,” Int J Nanomedicine, vol. 6, pp. 683–692, 2011, doi: 10.2147/ijn.s17386.